Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Isovue-128

(Iopamidol)

Phase 2Small molecule

BBracco Diagnostics, Inc

Isovue-128 is one of 68 small molecule programs targeting Metastasis. It is currently in Phase 2.

3

Indications

13

Total Trials

1

Active Trials

67

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Liposomal BupivacaineRecruiting

Adverse EventsUnknown status

MetastasisPreclinical

Active, not recruiting

Liposomal BupivacainePhase 2

Recruiting

Adverse EventsPreclinical

Unknown status

Competition

Competitive Landscape

64 competitors in Metastasis

#DrugCompanyPhaseTrials

Femara

Camptosar

Gemzar

Johnson & Johnson

Norvir

Neoral

Zometa

Lynparza

Tukysa

Verzenio

Keytruda

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Liposomal Bupivacaine

NCT06411795

Clinical

Trials by Indication[1]

MPR1 trial

Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)

Completed·AAzienda Policlinico Umberto I·Phase 4·NCT02040285·52 enrolled

Clinical Trial1 trial

Customized Contrast Media Dose Clinical Trial

Terminated·—·N/A·NCT02433665·166 enrolled

ART1 trial

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Completed·GGE Healthcare·Phase 4·NCT01475097·255 enrolled

Kidney1 trial

Kidney Damage in Patients With Moderate Fall in eGFR

Completed·BBracco Diagnostics, Inc·Phase 4·NCT01136876·57 enrolled

Metastasis1 trial

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Completed·MM.D. Anderson Cancer Center·N/A·NCT04870645·15 enrolled

7 more indications

Breast Cancer1 trial

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Terminated·JJennifer Lee Caswell-Jin·Phase 1·NCT04504331·4 enrolled

Contrast Agent1 trial

Optimization of Contrast Agent Dose in CT With Lean Body Weight

Completed·IIRCCS Policlinico S. Donato·Phase 4·NCT03384979·274 enrolled

Adverse Events1 trial

Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA

Unknown status·—·N/A·NCT05489055·500 enrolled

Liposomal Bupivacaine1 trial

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06411795·78 enrolled

Imaging1 trial

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

Completed·GGE Healthcare·Phase 4·NCT01376089·304 enrolled

Oral1 trial

Study With Oral Isovue in Abdominopelvic CT

Completed·BBracco Diagnostics, Inc··NCT04453059·218 enrolled

Unspecified2 trials

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

Completed·—·Phase 4·NCT03557385·201 enrolled

Isovue in Peripheral Digital Subtraction Angiography (DSA)

Completed·BBracco Diagnostics, Inc·Phase 4·NCT01075217·174 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 21, 1986

ISOVUE-128

NDA NDA018735

Oct 12, 1994

ISOVUE-200

NDA NDA020327

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Iopamidol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iopamidol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iopamidol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020327). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBracco Diagnostics, Inc

Related News